- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Inglewood, California • Los Angeles, California • Palo Alto, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–84
of 84
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 114 participants
- Timeline
- 1995 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
- Interventions
- LASN01, Placebo
- Drug
- Lead sponsor
- Lassen Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • St Louis, Missouri • Bellaire, Texas
- Conditions
- Thyroid Eye Disease
- Interventions
- Hyaluronic Acid Gel injection, Saline injection
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Orland Park, Illinois • Ann Arbor, Michigan + 8 more
- Conditions
- Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
- Interventions
- Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
- Procedure · Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Batoclimab, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Pasadena, California • San Francisco, California • Torrance, California + 12 more
- Conditions
- Thyroid Eye Disease, Graves' Orbitopathy
- Interventions
- Teprotumumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
- Conditions
- Thyroid Eye Disease
- Interventions
- VRDN-003, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more